These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 12879008)

  • 1. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.
    Miething C; Grundler R; Fend F; Hoepfl J; Mugler C; von Schilling C; Morris SW; Peschel C; Duyster J
    Oncogene; 2003 Jul; 22(30):4642-7. PubMed ID: 12879008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
    Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
    Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
    Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
    Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
    Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
    Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
    Turner SD; Tooze R; Maclennan K; Alexander DR
    Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.
    Kuefer MU; Look AT; Pulford K; Behm FG; Pattengale PK; Mason DY; Morris SW
    Blood; 1997 Oct; 90(8):2901-10. PubMed ID: 9376569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
    Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
    Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
    Hsu FY; Zhao Y; Anderson WF; Johnston PB
    Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
    Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.
    Turner SD; Merz H; Yeung D; Alexander DR
    Anticancer Res; 2006; 26(5A):3275-9. PubMed ID: 17094440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
    Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
    Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
    Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
    Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
    Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F
    Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
    Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
    Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
    Turner SD; Alexander DR
    Leukemia; 2005 Jul; 19(7):1128-34. PubMed ID: 15902287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
    Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
    Kalinova M; Krskova L; Brizova H; Kabickova E; Kepak T; Kodet R
    Leuk Res; 2008 Jan; 32(1):25-32. PubMed ID: 17320171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.